参附注射液联合盐酸埃克替尼在表皮生长因子受体阳性中晚期非小细胞肺癌患者中的应用效果  

Application effect of Shenfu injection combined with icotinib hydrochloride in patients with epidermal growth factor receptor-positive advanced non-small cell lung cancer

作　　者：魏骏扬 朱景瑶 杨芳 WEI Junyang;ZHU Jingyao;YANG Fang(School of Clinical Medicine,Hubei Enshi College,Enshi 445000,Hubei,China;School of Clinical Medicine,Tianjin Medical University,Tianjin 300270,China;Department of Oncology,Enshi Central Hospital,Enshi 445000,Hubei,China)

机构地区：[1]湖北恩施学院临床医学系,湖北恩施445000 [2]天津医科大学临床医学院,天津300270 [3]恩施市中心医院肿瘤内科,湖北恩施445000

出　　处：《癌症进展》2025年第2期150-153,共4页Oncology Progress

摘　　要：目的探讨参附注射液联合盐酸埃克替尼在表皮生长因子受体(EGFR)阳性中晚期非小细胞肺癌患者中的应用效果。方法选取100例EGFR阳性中晚期非小细胞肺癌患者,采用随机数字表法分为研究组和对照组,每组50例,对照组患者接受盐酸埃克替尼治疗,研究组患者接受参附注射液联合盐酸埃克替尼治疗。比较两组患者的肾功能(血肌酐、尿素氮、内生肌酐清除率)、肝功能[丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、总胆红素(TBIL)]、免疫功能(CD3^(+)、CD4^(+)、CD8^(+)水平及CD4^(+)/CD8^(+))、功能状态[美国东部肿瘤协作组(ECOG)体力状况(PS)评分、卡氏功能状态(KPS)评分]、生活质量[肺癌患者生命质量测定量表(FACT-L)]。结果治疗后,研究组患者血肌酐、尿素氮、ALT、AST、TBIL、CD8^(+)水平及ECOG PS评分均低于对照组,内生肌酐清除率、CD3^(+)水平、CD4^(+)水平、CD4^(+)/CD8^(+)、KPS评分、FACT-L各维度评分及总分均高于对照组,差异均有统计学意义(P﹤0.05)。结论参附注射液联合盐酸埃克替尼应用于EGFR阳性中晚期非小细胞肺癌患者中,可以改善肾功能、肝功能、免疫功能、功能状态及生活质量。Objective To explore the application effect of Shenfu injection combined with icotinib hydrochloride in patients with epidermal growth factor receptor(EGFR)-positive advanced non-small cell lung cancer.Method A total of 100 patients with EGFR-positive advanced non-small cell lung cancer were selected and divided into study group and control group by random number table method,with 50 cases in each group.Patients in the control group received icotinib hydrochloride treatment,and patients in the study group received Shenfu injection combined with icotinib hydrochloride treatment.The renal function(blood creatinine,urea nitrogen,endogenous creatinine clearance rate),liver function[alanine aminotransferase(ALT),aspartate aminotransferase(AST),total bilirubin(TBIL)],immune function(CD3^(+),CD4^(+),CD8^(+)levels and CD4^(+)/CD8^(+)),functional status[Eastern Cooperative Oncology Group(ECOG)performance status(PS)score,Karnofsky performance status(KPS)score],and quality of life[functional assessment of cancer therapy-lung(FACT-L)]were compared between the two groups.Result After treatment,the levels of blood creatinine,urea nitrogen,ALT,AST,TBIL,CD8^(+),and ECOG PS score in the study group were lower than those in the control group,the endogenous creatinine clearance rate,CD3^(+)level,CD4^(+)level,CD4^(+)/CD8^(+),KPS score,dimensional scores and total score of FACT-L were higher than those in the control group,and the differences were statistically significant(P<0.05).Conclusion Shenfu injection combined with icotinib hydrochloride can improve renal function,liver function,immune function,functional status and quality of life in patients with EGFR-positive advanced non-small cell lung cancer.

关 键 词：参附注射液 盐酸埃克替尼 表皮生长因子受体阳性 中晚期非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]